PE con una dosis de 1,3 mg/m2 dos veces a la semana excluídos)
English translation: DP
| GLOSSARY ENTRY (DERIVED FROM QUESTION BELOW) | ||||||
|---|---|---|---|---|---|---|
|
| 20:18 May 24, 2022 |
| Spanish to English translations [PRO] Medical - Medical: Pharmaceuticals / clinical trial | |||||
|---|---|---|---|---|---|
|
| ||||
|  Selected response from: María Patricia Arce Argentina Local time: 16:21 | ||||
Grading comment
| |||||
| Summary of answers provided | ||||
|---|---|---|---|---|
| 4 +1 | DP |
|
| Discussion entries: 1 | |
|---|---|
Answers
17 hrs confidence: 
peer agreement (net): +1
peer agreement (net): +1DP Explanation: Se excluyen los pacientes que presentan progresión de la enfermedad (PE) a esa dosis PE>DP (disease progression ) Ref: La reacción de exacerbación tumoral (RET) ha ocurrido durante el uso experimental de lenalidomida para la LLC y el linfoma, y se caracteriza por una inflamación sensible de los ganglios linfáticos, fiebre de bajo grado, dolor y erupción cutánea. Lenalidomida no está indicado y no se recomienda para su uso en la LLC fuera de los ensayos clínicos controlados. Se recomienda el monitoreo y la evaluación de la RET en pacientes con LCM, LF o LZM. La reacción de exacerbación del tumor puede imitar la progresión de la enfermedad (PE). https://www.eurofarma.cl/productos/prospecto/patient/bula-nu... Se recomienda el control y la evaluación de las reacciones de llamarada en el tumor en pacientes con LCM La reacción de llamarada en el tumor puede imitar la progresión de la enfermedad (PE). https://www.ispch.cl/sites/default/files/revlimid_capsulas_1... * Deben tener recidiva, resistencia o progresión de la enfermedad (PE) documentadas después del tratamiento sistémico: https://www.ensayoshematologiamadrid.es/ensayo-clinico/358-f... Tumor Flare Reaction (TFR): TFR has occurred during investigational use of REVLIMID for CLL and lymphoma. Monitoring and evaluation for TFR is recommended in patients with MCL, FL or MZL. Tumor flare may mimic the progression of disease (PD). Progression-Free Survival (PFS) | REVLIMID® (lenalidomide) + rituximab (revlimidhcp.com) Experimental: Arm A (bortezomib, lenalidomide, dexamethasone) Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. https://clinicaltrials.gov/ct2/show/NCT01863550 |
| |
Grading comment
| ||
| Login to enter a peer comment (or grade) | ||
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.
KudoZ™ translation help
The KudoZ network provides a framework for translators and others to assist each other with translations or explanations of terms and short phrases.
See also:
Search millions of term translations